Nkarta (NKTX) Revenue (2019)
Nkarta's (NKTX) quarterly Revenue came in at -$385.0 in Q3 2019, down 116.68% quarter-over-quarter from $2308.0 in Q2 2019.
Nkarta (NKTX) Revenue (2019) Analysis & Trends
Nkarta's Revenue history runs 1 years deep, the most recent figure standing at -$385.0 for Q3 2019.
- On a quarterly basis, Revenue changed N/A year-over-year to -$385.0 in Q3 2019; TTM through Dec 2020 was -$385.0, a N/A change from a year earlier, with the FY2019 full-year figure at $115000.0, changed N/A from the prior year.
- Revenue fell to -$385.0 in Q3 2019 per NKTX's latest filing, from $2308.0 in the prior quarter.
- Across five years, Revenue topped out at $2308.0 in Q2 2019 and bottomed at -$385.0 in Q3 2019.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 1.51 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 2.99 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 3.61 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 1.56 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Nkarta | 170.79 Mn | 170.79 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2019 | -385.00 |
| Jun 30, 2019 | 2,308.00 |